HiberCell

Pre-clinical

New York, United StatesFounded 2018hibercell.com

HiberCell is advancing a novel oncology platform focused on the Integrated Stress Response (ISR), a critical pathway cancer cells use to survive treatment and drive relapse. The company has three clinical-stage assets: HC-7366 and HC-5404, which target key ISR kinases, and odetiglucan, an immune modulator. With strategic collaborations and a leadership team of seasoned biotech executives, HiberCell is positioning itself to address significant unmet needs in resistant and metastatic cancers.

Founded

2018

Focus

DiagnosticsSmall Molecules

AI Company Overview

Technology Platform

A platform targeting the Integrated Stress Response (ISR) to exploit adaptive-stress driven vulnerabilities in cancer cells, utilizing both kinase modulation (GCN2 activation, PERK inhibition) and immune reprogramming.

Funding History

Total raised: $60.7M

Series BUndisclosedUndisclosedMar 15, 2021

Series A$60.7MARCH Venture PartnersOct 15, 2019

Opportunities

HiberCell's primary growth opportunity lies in successfully demonstrating clinical proof-of-concept for its novel ISR-targeting approach, which could unlock significant value across multiple cancer types.

The broad applicability of its mechanisms in combination with standard-of-care therapies presents numerous potential partnership and label expansion opportunities.

Success in liver metastasis with odetiglucan could address a major unmet need in oncology.

Risk Factors

Key risks include the inherent uncertainty of early clinical trials for first-in-class mechanisms, potential difficulty in identifying optimal patient populations and combination regimens, and reliance on future partnerships or financing to advance its pipeline.

The complex biology of the ISR may lead to unpredictable efficacy or safety profiles.

Competitive Landscape

HiberCell faces competition from other companies exploring ER stress and innate immune pathways, but its first-in-class GCN2 activator (HC-7366) provides differentiation. Its main competitors are other biotechs in the emerging stress-pathway oncology space, as well as developers of next-generation immune-oncology agents. HiberCell's integrated platform approach and focus on treatment resistance are its key competitive advantages.